08:00 AM EDT, 08/15/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) made an equity investment in Abata Therapeutics to support the development of the latter's Treg cell therapy products, Abata said Thursday.

In addition to the financial support, Bristol-Myers will add expertise to Abata's two main programs -- ABA-101 for the treatment of progressive multiple sclerosis and ABA-201 for the treatment of type 1 diabetes, Abata President and Chief Executive Samantha Singer said.

Financial terms of the investment were not disclosed.

Price: 48.80, Change: +0.39, Percent Change: +0.81